Vladimir J.N. Bykov, MD PhD
Currently I am holding position of Associate Professor in experimental oncology at Bioclinicum, Karolinska Institutet, Solna, Sweden.
In parallel I am working as a consultant in the area of drug development at APREA Therapeutics AB.
My job carrier encompasses experience in medicine, cancer research, teaching, analytical chemistry, drug development, data analysis and programming in R, Python, HTML and CSS. I am holding several patents on drug discovery.
I am one of the founders of APREA Therapeutics AB. The foundation of the company was my discovery of APR-246 anti-cancer compound which now is taken into Phase III clinical trial. APR-246 is first clinically relevant drug which able to restore native conformation and tumour suppressor activity to a mutant p53 protein. Mutations in p53 gene are the leading cause behind tumour development and resistance to current therapeutic interventions, thus resetting this part of tumour development renders cancer cells vulnerable to treatment.
My interests
My interests include travelling, diving and martial arts training.
Here are the clubs in Stockholm area where I enjoy training and I recommend these places to anybody with similar interests:
